Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) Debt to Equity (2020 - 2023)

Historic Debt to Equity for C4 Therapeutics (CCCC) over the last 4 years, with Q2 2023 value amounting to $0.04.

  • C4 Therapeutics' Debt to Equity rose 3701.32% to $0.04 in Q2 2023 from the same period last year, while for Jun 2023 it was $0.04, marking a year-over-year increase of 3701.32%. This contributed to the annual value of $0.04 for FY2022, which is 4363.45% up from last year.
  • Latest data reveals that C4 Therapeutics reported Debt to Equity of $0.04 as of Q2 2023, which was up 3701.32% from $0.04 recorded in Q1 2023.
  • In the past 5 years, C4 Therapeutics' Debt to Equity ranged from a high of $0.04 in Q2 2023 and a low of -$0.06 during Q3 2020
  • Moreover, its 4-year median value for Debt to Equity was $0.03 (2022), whereas its average is $0.03.
  • The largest annual percentage gain for C4 Therapeutics' Debt to Equity in the last 5 years was 14191.49% (2021), contrasted with its biggest fall of 2279.59% (2021).
  • Quarter analysis of 4 years shows C4 Therapeutics' Debt to Equity stood at $0.04 in 2020, then dropped by 22.8% to $0.03 in 2021, then skyrocketed by 43.63% to $0.04 in 2022, then increased by 11.4% to $0.04 in 2023.
  • Its Debt to Equity was $0.04 in Q2 2023, compared to $0.04 in Q1 2023 and $0.04 in Q4 2022.